Samsung Biologics management and the company's labor union failed to reach an agreement during negotiations on Monday morning [1].
The stalemate threatens the operational stability of the Songdo plant, as the strike enters its fourth day [1]. Prolonged labor unrest at one of the world's largest contract development and manufacturing organizations could disrupt critical biopharmaceutical production schedules.
The meeting began at 10 a.m. and lasted approximately two hours [1]. Despite the discussion, both parties left the session without a resolution. Talks later resumed at 1:30 p.m. to continue the dialogue [1].
Disagreements center on wage increases, bonuses, and personnel issues [2]. The union demanded that management withdraw all strike-related actions and lawsuits without requiring concessions from the workers [2]. Management said that lowering the intensity of the labor dispute without any gains for the company was unacceptable [2].
Representatives for the union said the company's refusal to withdraw lawsuits remains a primary point of contention. The strike has now persisted for four days [1], with both sides indicating that further negotiations will proceed to find a middle ground [1].
The Songdo plant serves as the primary hub for the company's manufacturing capabilities. While the exact impact on current output remains undisclosed, the continued absence of a labor agreement maintains a state of uncertainty for the facility's workforce [1].
“Samsung Biologics management and the company's labor union failed to reach an agreement during negotiations.”
The deadlock at Samsung Biologics highlights a growing tension between South Korean corporate management and labor unions regarding legal retaliation for strike actions. By demanding the withdrawal of lawsuits as a prerequisite for ending the strike, the union is attempting to shift the power dynamic regarding labor rights in the high-stakes biopharmaceutical sector.
